An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
NCT ID: NCT01930786
Last Updated: 2019-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
744 participants
OBSERVATIONAL
2013-10-16
2017-10-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
NCT01387074
A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.
NCT04396704
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
NCT06150729
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
NCT04936542
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
NCT01603459
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
onabotulinumtoxinA
onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
onabotulinumtoxinA
onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
onabotulinumtoxinA
onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to complete study questionnaires and answer study questions by phone or internet
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aleks Zuzek
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loma Linda University School Of Medicine
Loma Linda, California, United States
MS Center of California
Newport Beach, California, United States
Sutter Health General Hospital
Sacramento, California, United States
Design Neuroscience Center
Doral, Florida, United States
Brooks Rehabilitation Hospital
Jacksonville, Florida, United States
Emerald Coast Center for Neurological Disorders
Pensacola, Florida, United States
Gil, Ramon A.
Port Charlotte, Florida, United States
Kernan Hospital
Baltimore, Maryland, United States
MedTechnical, PLLC
Silver Spring, Maryland, United States
Michigan Institute for Neurological Disorders
Farmington Hills, Michigan, United States
The Curators of the University of Missouri on behalf of University of Missouri Health Care
Columbia, Missouri, United States
Seacoast Physiatry
Exeter, New Hampshire, United States
CentraState Medical Center
Freehold, New Jersey, United States
Guilford Neurologic Associates
Greensboro, North Carolina, United States
Dayton Center for Neurological Disorders
Dayton, Ohio, United States
Albert Einstein Healthcare Network, Moss Rehabilitation Hospital
Elkins Park, Pennsylvania, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Penn Medicine Rittenhouse
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Health System
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Metrolina Neurological Assoc., PA
Rock Hill, South Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Memorial Hermann Hospital
Houston, Texas, United States
Scott & White Memorial Hospital
Temple, Texas, United States
Swedish Neuroscience Institute
Seattle, Washington, United States
Center for Neurological Disorders, S.C.
Milwaukee, Wisconsin, United States
Hôpital Morvan
Brest, Finistere, France
Pôle Saint Helier
Rennes, Ille Et Vilaine, France
CHU de Grenoble - Hôpital Sud
Échirolles, Isere, France
Hopital Saint Philibert - GHICL Lille
Lomme, Nord, France
Centre Hospitalier de Pau
Pau, Pyrenees Atlantiques, France
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
Universitaetsklinikum Muenster
Münster, North Rhine-Westphalia, Germany
Universitaetsklinikum Leipzig AoeR
Leipzig, Saxony, Germany
Universitaetsklinikum Jena
Jena, Thuringia, Germany
Parkinson Klinik Wolfach GmbH & Co KG
Baden Wuerttemberg, , Germany
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
Bari, , Italy
Ospedale San Raffaele
Milan, , Italy
Azienda Ospedaliero - Universitaria Maggiore delle Carità
Novara, , Italy
Policlinico Universitario Agostino Gemelli
Roma, , Italy
Hospital Universitario Mutua de Terrassa
Terrassa, Barcelona, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Hospital de Conxo (Santiago de Compostela) GALICIA
Santiago de Compestela, Pontevedra, Spain
Hospital del Mar
Barcelona, , Spain
Vall d'Hebron Institut de Recerca-VHIR
Barcelona, , Spain
Hospital Clinic i Provincial de Barcelona
Barcelona, , Spain
Complejo Hospitalario de Pontevedra
Pontevedra, , Spain
Taipei Medical University Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital, Linkou
Taoyuan, , Taiwan
The National Hospital for Neurology & Neurosurgery
London, Greater London, United Kingdom
Birch Hill Hospital
Rochdale, Greater Manchester, United Kingdom
Kent and Canterbury Hospital
Kent, Kent, United Kingdom
The Walton Centre
Liverpool, Merseyside, United Kingdom
Nottingham University Hospitals City Campus
Nottingham, Nottinghamshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wissel J, List C, Schwartz M, Nelson M, Musacchio T, Duarte E. Relief of pain associated with spasticity in adult patients after treatment with onabotulinumtoxinA: Post hoc observational results from the ASPIRE study. PM R. 2025 Sep 30. doi: 10.1002/pmrj.70013. Online ahead of print.
Bavikatte G, Francisco GE, Jost WH, Baricich A, Duarte E, Tang SFT, Schwartz M, Nelson M, Musacchio T, Esquenazi A. Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study. PM R. 2024 Nov;16(11):1175-1189. doi: 10.1002/pmrj.13195. Epub 2024 May 30.
Bavikatte G, Esquenazi A, Dimyan MA, Dashtipour K, Feng W, Mayadev A, Fanning K, Musacchio T, Zuzek A, Francisco GE. Safety and Real-World Dosing of OnabotulinumtoxinA for the Treatment of Adult Spasticity: Post Hoc Analysis of the Adult Spasticity International Registry Study. Am J Phys Med Rehabil. 2024 Jul 1;103(7):580-587. doi: 10.1097/PHM.0000000000002410. Epub 2024 Jan 8.
Esquenazi A, Francisco GE, Feng W, Baricich A, Gallien P, Fanning K, Zuzek A, Bandari DS, Wittenberg GF. Real-World Adherence to OnabotulinumtoxinA Treatment for Spasticity: Insights From the ASPIRE Study. Arch Phys Med Rehabil. 2021 Nov;102(11):2172-2184.e6. doi: 10.1016/j.apmr.2021.06.008. Epub 2021 Jul 7.
Esquenazi A, Bavikatte G, Bandari DS, Jost WH, Munin MC, Tang SFT, Largent J, Adams AM, Zuzek A, Francisco GE. Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity. PM R. 2021 Oct;13(10):1079-1093. doi: 10.1002/pmrj.12517. Epub 2021 Jan 11.
Francisco GE, Jost WH, Bavikatte G, Bandari DS, Tang SFT, Munin MC, Largent J, Adams AM, Zuzek A, Esquenazi A. Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study. PM R. 2020 Nov;12(11):1120-1133. doi: 10.1002/pmrj.12328. Epub 2020 Feb 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMA-BTX-SP-12-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.